#USA #Boston #cancer detection #TOBY Inc. #Matthew Collier

TOBY Inc. Expands Leadership with Matthew Collier as New Independent Director

In a strategic move, TOBY, Inc., a pioneering company in noninvasive multi-cancer early detection, has announced the appointment of Matthew Collier as an independent director of its Board. This decision reflects TOBY's commitment to advancing healthcare innovation and improving cancer detection methods.

Matthew Laskowski, the CEO of TOBY, expressed his enthusiasm about this addition, stating that Collier's strategic expertise and visionary outlook would be vital as the company strives to accelerate its path to market. Laskowski remarked, "Matthew Collier's strategic experience and vision for healthcare innovation will be an invaluable asset to TOBY as we accelerate our path to market."

With over 30 years of leadership experience in digital health, strategy, and life sciences, Collier brings a wealth of knowledge to the table. He currently serves as the President and Chief Commercial Officer at Otonoma. Here, he is leading the charge towards the commercialization of the world's first secure distributed intelligence network in collaboration with tech giants Accenture and Nvidia.

Reflecting on his new role at TOBY, Collier stated, "I've spent my career at the intersection of healthcare, technology, and transformation, and I believe TOBY represents the next wave of innovation in early cancer detection. The opportunity to bring noninvasive, accessible testing to millions of people is not only disruptive, but also profoundly important in our fight against cancer."

As an independent director, Collier's focus will be on providing objective oversight and strategic guidance as TOBY moves towards the commercialization of its groundbreaking technologies. He joins a Board that hosts other esteemed professionals, which includes:

• - Matthew Laskowski, CEO
• - Dragan Sebisanovic, Chief Scientific Officer
• - John Leggett, Director at Osterbury Capital LLC
• - Joseph Hanssen, Director at Osterbury Capital LLC
• - Matthew Collier, Independent Director

Collier's extensive career boasts achievements such as raising over $500 million in private equity and venture capital. His previous position as CEO of Sutherland Healthcare Solutions saw him lead the organization through a successful turnaround that delivered double-digit growth through AI-enabled digital platforms. Moreover, he has held high-ranking positions at noteworthy firms like Accenture, Bain & Company, and McKinsey & Company, accumulating experience across North America, Europe, China, and the Asia-Pacific region.

Collier's academic credentials are equally impressive, holding an MBA from Northwestern University's Kellogg School of Management and a BS in Mechanical Engineering from Stanford University.

TOBY, inspired by Sherlock Holmes's Bloodhound, focuses on the early detection of cancer through innovative means such as spectroscopy and artificial intelligence. The company has developed a groundbreaking single urine test capable of detecting 10 forms of cancer, which accounts for over 60% of all new cancer cases globally. This test works by identifying the unique molecular signatures associated with various cancers, combining the precision of spectroscopy, biomarker changes, and advanced computational algorithms. This revolutionary approach in early screening aims to deliver accessible and affordable cancer detection solutions.

For more information on TOBY and its initiatives, please visit Toby.health.